Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 13/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21585093 | 0.77 | OPRM1 (0.31) | OPRL1OPRM1 | |
| SCHEMBL824131 | 0.76 | OPRL1 (0.49) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL22047752 | 0.74 | OPRM1 (0.30) | OPRL1OPRM1 | |
| SCHEMBL105239 | 0.74 | NCF1 (0.40) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL24827933 | 0.74 | OPRL1 (0.41) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3966801 | 0.72 | NOS3 (0.30) | — | |
| SCHEMBL408516 | 0.72 | CHRNA7 (0.34) | — | |
| SCHEMBL20353674 | 0.72 | — | — | |
| SCHEMBL24004088 | 0.72 | — | — | |
| SCHEMBL19964503 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20190350906-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2019-11-21 | — | — | US | disclosed |
| EP-2427195-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2019-05-01 | — | — | EP | disclosed |
| CN-104703979-B | Heterocyclic compounds and their use | 无限药品股份有限公司 | 2018-11-27 | — | — | CN | disclosed |
| EP-2467141-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2018-02-15 | — | — | US | disclosed |
| US-9718815-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| EP-2734520-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2012-12-27 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012148540-A1 | COMBINATION OF KANASE INHIBITORS AND USES THREOF | INTELLIKINE, LLC (US) | 2012-11-01 | — | — | WO | disclosed |
| EP-2467141-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Intellikine, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2427195-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Intellikine, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2011149937-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011022439-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
| WO-2010129816-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | OPRL1 3865/4885OPRM1 3110/4885OPRK1 1439/4885 |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | OPRL1 3702/4885OPRM1 2492/4885OPRK1 1066/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | OPRL1 3702/4885OPRM1 2492/4885OPRK1 1066/4885 |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | OPRL1 3865/4885OPRM1 3110/4885OPRK1 1439/4885 |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | OPRL1 3865/4885OPRM1 3110/4885OPRK1 1439/4885 |
| US-20190350906-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | OPRL1 3865/4885OPRM1 3110/4885OPRK1 1439/4885 |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | OPRL1 3976/4885OPRM1 3654/4885OPRK1 1461/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | OPRL1 3298/4885OPRM1 4514/4885OPRK1 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.